Toward Optimum Benefit‐Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles

Abstract

Delay in approval (“drug lag”) of new anticancer therapies in Asia has led to increased interest in simultaneous global clinical development inclusive of Asia. Anticancer agents often have a narrow therapeutic window, making characterization of pharmacokinetics (PKs), pharmacodynamics, and safety crucial for maximizing benefit/risk in Asian populations… (More)
DOI: 10.1111/cts.12386

Topics

8 Figures and Tables

Slides referencing similar topics